Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

Not yet recruiting

• Conditions: Relapsed Cancer; Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
• Interventions: Biological: Relapsed glioblastoma

• Registration Number: NCT06430424
• Lead Sponsor: University Hospital, Bordeaux

Brief Summary

Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.

Detailed Description

Glioblastomas are the most frequent and aggressive malignant Central Nervous System (CNS) tumors in adults, with a median survival of only 14 months.

Current treatment is based on surgery followed by radiochemotherapy (STUPP protocol), unchanged since 2005. Clinical trials evaluating immune checkpoint inhibitors and targeted therapies have largely failed to demonstrate efficacy in these tumors. In order to better understand the oncogenesis of glioblastoma and identify potential new therapeutic targets, the study of the characteristics of relapsed tumors compared with the initial tumor seems relevant.

The aim of this retrospective study is to investigate the transcriptomic, proteomic and metabolic characteristics of relapsed glioblastomas reoperated at the University Hospital of Bordeaux, France, between 2005 and 2023, for which tumor material is available. These analyses will be correlated with relapse-free and overall survival of the patients.

Study Timeline

• Study First Submitted: 2024-03-27
• Status Verified: 2024-05
• Study First Submitted QC: 2024-05-23
• Study First Posted: 2024-05-28
• Study Start: 2024-06
• Last Update Submitted: 2024-06-24
• Last Update Posted: 2024-06-25
• Primary Completion: 2025-07
• Study Completion: 2026-04

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• age > 18 years
• surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux

Exclusion Criteria

• systemic therapy received for non-glioblastoma tumor

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients operated for primary and recurrent glioblastoma	Relapsed glioblastoma	Patients operated for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux

Primary Outcome Measures

Name	Time	Method
Evaluation of metabolic changes involved in glioblastoma relapse	Up to 2 years after the start of the study	Relative abondance of metabolite and differential enzyme expression in a recurrence versus primary sample

Secondary Outcome Measures

Name	Time	Method
Overall survival	From date of the second surgery until the date of death from any cause, assessed up to 5 years	Overall survival of patients who underwent surgery for relapse glioblastoma after the surgery of relapse
Progression-free survival	From date of the second surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years	Progression-free survival of patients who underwent surgery for relapse glioblastoma after the surgery of relapse measured at time of inclusion

Trial Locations

Locations (1)

CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale; 🇫🇷 Bordeaux, France